7 assets in Collecting Duct Carcinoma

Therapeutic assets addressing Collecting Duct Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Collecting Duct Carcinoma	Bradley A. McGregor, MD	P2	B (57)
Axitinib Collecting Duct Carcinoma	Peking University Cancer Hospital & Institute	P2	CCC (53)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Collecting Duct Carcinoma	Giuseppe Procopio	P2	CCC (53)
Ipilimumab Collecting Duct Carcinoma	Bradley A. McGregor, MD	P2	CCC (53)
Nivolumab Collecting Duct Carcinoma	Bradley A. McGregor, MD	P2	CCC (53)
Pamiparib Collecting Duct Carcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (53)
Pembrolizumab Collecting Duct Carcinoma	Giuseppe Procopio	P2	CCC (53)